Prospective mapping of viral mutations that escape antibodies used to treat COVID-19
Open accessPublished version of a preprint
The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Mapping antibody escape in SARS-CoV-2: Several antibodies are in use or under development as therapies to treat COVID-19. As new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants emerge, it is important to predict whether they will remain susceptible to antibody treatment. Starr et al. used a yeast library that covers all mutations to the SARS-CoV-2 receptor-binding domain that do not strongly disrupt binding to the host receptor (ACE2) and mapped how these mutations affect binding to three leading anti–SARS-CoV-2 antibodies. The maps identify mutations that escape antibody binding, including a single mutation that escapes both antibodies in the Regeneron antibody cocktail. Many of the mutations that escape single antibodies are circulating in the human population. Science , this issue p. 850
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Fig. 2 Escape maps are consistent with viral mutations selected in cell culture and a persistently infected patient. (A) Viral escape mutations selected by Regeneron with spike-pseudotyped VSV in cell culture in the presence of antibody (12). (B) Escape maps like those in Fig. 1A, but showing only mutations accessible by single-nucleotide changes to the Wuhan-Hu-1 sequence, with nongray colors indicating mutations in cell culture (red), the infected patient (blue), or both (purple). Figure S5 shows these maps colored by how mutations affect ACE2 affinity or RBD expression. (C) Dynamics of RBD mutations in a patient treated with REGN-COV2 at day 145 of infection (black dot-dash vertical line). E484A rose in frequency in linkage with F486I, but because E484A is not an escape mutation in our maps, it is not shown in other panels. See also fig. S4. (D) The escape mutations that arise in cell culture and the infected patient are single-nucleotide–accessible and escape antibody binding without imposing a large cost on ACE2 affinity [as measured using yeast display (7)]. Each point is a mutation, with shape and color indicating whether it is accessible and selected during viral growth. Points farther to the right on the x axis indicate stronger escape from antibody binding; points higher up on the y axis indicate higher ACE2 affinity.](https://figures.cochat.ai/paper-figures/91cf075ab18741e0a80bfb01ad2b708a/prospective-mapping-of-viral-mutations-that-escape-antibodies-used-to-treat-figure-2.jpg)

![Fig. 4 Structural context of escape mutations. (A) Escape maps projected on antibody-bound RBD structures. [REGN10933 and REGN10987: Protein Data Bank (PDB) ID 6XDG (11); LY-CoV016: PDB ID 7C01 (13)]. Antibody heavy- and light-chain variable domains are shown as blue cartoons, and the RBD surface is colored to indicate how strongly mutations at that site mediate escape (white indicates no escape, red indicates strongest escape site for that antibody or cocktail). Sites where no mutations are functionally tolerated are colored gray. (B) For each antibody, sites were classified as direct antibody contacts (non-hydrogen atoms within 4 Å of antibody), antibody-proximal (4 to 8 Å), or antibody-distal (>8 Å). Each point indicates a site, classified as escape (red) or non-escape (black). The dashed gray line indicates the cutoff used to classify sites as escape or non-escape (see materials and methods for details). Red and black numbers indicate how many sites in each category are escape or non-escape sites, respectively. Interactive visualizations are at https://jbloomlab.github.io/SARS-CoV-2-RBD_MAP_clinical_Abs/, and hypothesized mechanisms of escape and additional structural details for labeled points are shown in fig. S6.](https://figures.cochat.ai/paper-figures/854cbba408614d74b93381682c26dd9e/prospective-mapping-of-viral-mutations-that-escape-antibodies-used-to-treat-figure-4.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A475V is resistant to class 1 antibodies (structurally defined as described29); E484K and Q493R are resistant to class 2 antibodies7,8,12,13,29,30,32,33; while R346S, N439K, and N440K are resistant to class 3 antibodies7,8,12,13,29,33.”
From mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants (2021) · cites this paper as [32]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several of the RBD mutations directly affect angiotensin-converting enzyme 2 (ACE2) receptor-binding affinity, which may affect infectivity, viral load, or transmissibility.11, 12, 13, 14”
From Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals (2021) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mutations found in emergent S variants decrease sensitivity to neutralization by mAbs, convalescent plasma, and sera from vaccinated individuals (27, 37, 58, 61–70).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [58]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The B.1.1.7, B.1.351, and P.1 lineages all harbor a N501Y mutation in the RBD, which increases the affinity for the ACE2 receptor (57, 58), and a D614G mutation, which increases virion spike density, infectivity, and transmissibility (59, 60).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [58]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We tested four clinically approved monoclonal antibodies that target the RBD 18,19 (bamlanivimab (LY-CoV555), etesevimab (LY-CoV016), casirivimab (REGN10933) and imdevimab (REGN10987))”
From Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization (2021) · cites this paper as [19]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MAFFT Multiple Sequence Alignment Software Version 7: Improvements in Performance and Usability
Katoh, K., & Standley, D. M. (2013) · Molecular Biology and Evolution · doi:10.1093/molbev/mst010 · Cited by 46,209
fastp: an ultra-fast all-in-one FASTQ preprocessor
Chen, S., Zhou, Y., Chen, Y., & Gu, J. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty560 · Cited by 29,721
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein
Walls, A. C., Park, Y.-J., Tortorici, M. A., Wall, A., McGuire, A. T., & Veesler, D. (2020) · doi:10.1101/2020.02.19.956581 · Cited by 8,586
Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM
Li, H. (2013) · DROPS (Schloss Dagstuhl – Leibniz Center for Informatics) · doi:10.48550/arxiv.1303.3997 · Cited by 5,159
Aligning sequence reads, clone sequences and assembly con*gs with BWA-MEM
Li, H. (2014) · arXiv (Cornell University) · doi:10.6084/m9.figshare.963153.v1 · Cited by 4,932
Structural basis of receptor recognition by SARS-CoV-2
Shang, J., Ye, G., Shi, K., Wan, Y., Luo, C., Aihara, H., Geng, Q., Auerbach, A., & Li, F. (2020) · Nature · doi:10.1038/s41586-020-2179-y · Cited by 3,661
Snakemake—a scalable bioinformatics workflow engine
Köster, J., & Rahmann, S. (2012) · Bioinformatics · doi:10.1093/bioinformatics/bts480 · Cited by 2,780
Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D., Pillay, S., San, E. J., Msomi, N., et al. (2020) · doi:10.1101/2020.12.21.20248640 · Cited by 2,535
Detection of a SARS-CoV-2 variant of concern in South Africa
Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D., Pillay, S., San, E. J., Msomi, N., et al. (2021) · Nature · doi:10.1038/s41586-021-03402-9 · Cited by 2,510
Research works printed but not linked: 2
- 10.1016/j.cell.2020.02.058 · doi:10.1016/j.cell.2020.02.058 · Paper page
- Regeneron Pharmaceuticals Inc. “Regeneron’s casirivimab and imdevimab antibody cocktail for COVID-19 is first combination therapy to receive FDA emergency use authorization ” press release (21 November 2020); https://investor.regeneron.com/news-releases/news-release-details/regenerons-regen-cov2-first-antibody-cocktail-covid-19-receive/.
Cited by
Items 101–200 of 750
Singh, J., Samal, J., Kumar, V., Sharma, J., Agrawal, U., Ehtesham, N. Z., Sundar, D., Rahman, S. A., Hira, S., & Hasnain, S. E. (2021) · Viruses · doi:10.3390/v13030439 · Cited by 125
Therapeutic targets and interventional strategies in COVID-19: mechanisms and clinical studies
Zhou, Y., Xie, Y., Tang, L., Pu, D., Zhu, Y., Liu, J., & Ma, X. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00733-x · Cited by 127
Accelerated SARS-CoV-2 intrahost evolution leading to distinct genotypes during chronic infection
Chaguza, C., Hahn, A. M., Petrone, M. E., Zhou, S., Ferguson, D. J. P., Breban, M. I., Pham, K., Peña-Hernández, M. A., Castaldi, C., Hill, V., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.100943 · Cited by 133
The Spike of Concern—The Novel Variants of SARS-CoV-2
Winger, A., & Caspari, T. (2021) · Viruses · doi:10.3390/v13061002 · Cited by 130
Jette, C. A., Cohen, A. A., Gnanapragasam, P. N. P., Muecksch, F., Lee, Y. E., Huey-Tubman, K. E., Schmidt, F., Hatziioannou, T., Bieniasz, P. D., Nussenzweig, M. C., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109760 · Cited by 116
“In addition, C118 and C022 antibodies were not affected by naturally occurring RBDmutations that undermine the activity of several antibodies approved for therapeutic use (Hoffmann et al., 2021; Starr et al., 2021b).”
Guo, Y., Han, J., Zhang, Y., He, J., Yu, W., Zhang, X., Wu, J., Zhang, S., Kong, Y., Guo, Y., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.877101 · Cited by 131
Zhang, S., Huang, W., Ren, L., Ju, X., Gong, M., Rao, J. Y., Sun, L., Li, P., Ding, Q., Wang, J., et al. (2021) · Cell Research · doi:10.1038/s41422-021-00581-y · Cited by 121
Hodcroft, E. B., Domman, D. B., Snyder, D. J., Oguntuyo, K. Y., Van Diest, M., Densmore, K. H., Schwalm, K. C., Femling, J., Carroll, J. L., Scott, R. S., et al. (2021) · medRxiv · doi:10.1101/2021.02.12.21251658 · Cited by 113
Taft, J. M., Weber, C. R., Gao, B., Ehling, R. A., Han, J., Frei, L., Metcalfe, S. W., Overath, M. D., Yermanos, A., Kelton, W., et al. (2022) · Cell · doi:10.1016/j.cell.2022.08.024 · Cited by 110
van Gils, M. J., Lavell, A. H. A., van der Straten, K., Appelman, B., Bontjer, I., Poniman, M., Burger, J. A., Oomen, M., Bouhuijs, J. H., van Vught, L. A., et al. (2022) · PLoS Medicine · doi:10.1371/journal.pmed.1003991 · Cited by 112
Dupont, L., Snell, L. B., Graham, C., Seow, J., Merrick, B., Lechmere, T., Maguire, T. J. A., Hallett, S. R., Pickering, S., Charalampous, T., et al. (2021) · Nature Microbiology · doi:10.1038/s41564-021-00974-0 · Cited by 110
COVID-19: Challenges of Viral Variants
Jacobs, J. L., Haidar, G., & Mellors, J. W. (2022) · Annual Review of Medicine · doi:10.1146/annurev-med-042921-020956 · Cited by 118
The Importance and Challenges of Identifying SARS-CoV-2 Reinfections
Babiker, A., Marvil, C. E., Waggoner, J. J., Collins, M. H., & Piantadosi, A. L. (2020) · Journal of Clinical Microbiology · doi:10.1128/jcm.02769-20 · Cited by 108
SARS-CoV-2 Evolution and Immune Escape in Immunocompromised Patients
Scherer, E. M., Babiker, A. Y. M., Adelman, M. W., Allman, B. E., Key, A., Kleinhenz, J., Langsjoen, R. M., Nguyen, P.-V., Onyechi, I., Sherman, J. D., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2202861 · Cited by 99
Neutralization of SARS‐CoV‐2 by highly potent, hyperthermostable, and mutation‐tolerant nanobodies
Guettler, T., Aksu, M., Dickmanns, A., Stegmann, K. M., Gregor, K., Rees, R., Taxer, W., Rymarenko, O., Schünemann, J., Dienemann, C., et al. (2021) · The EMBO Journal · doi:10.15252/embj.2021107985 · Cited by 98
“The emergence of such mutant strains is presumably driven by the selective pressure of the immune system, particularly in immunocompromised, persistently infected patients (Clark et al , 2021; Starr et al , 2021).”
Signatures in SARS-CoV-2 spike protein conferring escape to neutralizing antibodies
Alenquer, M., Ferreira, F., Lousa, D., Valério, M., Medina-Lopes, M., Bergman, M., Gonçalves, J., Demengeot, J., Leite, R. B., Lilue, J., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009772 · Cited by 107
Omicron BA.2 (B.1.1.529.2): High Potential for Becoming the Next Dominant Variant
Chen, J., & Wei, G. (2022) · The Journal of Physical Chemistry Letters · doi:10.1021/acs.jpclett.2c00469 · Cited by 112
Mechanistic Modeling of SARS‐CoV‐2 and Other Infectious Diseases and the Effects of Therapeutics
Perelson, A. S., & Ke, R. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2160 · Cited by 96
Evolutionary Landscapes of Host-Virus Arms Races
Tenthorey, J. L., Emerman, M., & Malik, H. S. (2022) · Annual Review of Immunology · doi:10.1146/annurev-immunol-072621-084422 · Cited by 96
Martin, D. P., Weaver, S., Tegally, H., San, E. J., Shank, S. D., Wilkinson, E., Lucaci, A. G., Giandhari, J., Naidoo, S., Pillay, Y., et al. (2021) · doi:10.1101/2021.02.23.21252268 · Cited by 291
Chen, L., Zody, M. C., Germanio, C. D., Martinelli, R., Mediavilla, J. R., Cunningham, M. H., Composto, K., Chow, K. F., Kordalewska, M., Corvelo, A., et al. (2021) · mSphere · doi:10.1128/msphere.00480-21 · Cited by 95
Borsche, L., Glauner, B., & von Mendel, J. (2021) · Nutrients · doi:10.3390/nu13103596 · Cited by 100
Silva, R. P., Huang, Y., Nguyen, A. W., Hsieh, C.-L., Olaluwoye, O. S., Kaoud, T. S., Wilen, R. E., Qerqez, A. N., Park, J.-G., Khalil, A. M., et al. (2023) · eLife · doi:10.7554/elife.83710 · Cited by 90
Choudhary, M. C., Crain, C. R., Qiu, X., Hanage, W. P., & Li, J. Z. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab380 · Cited by 83
“In addition, treatment with convalescent plasma or monoclonal antibody cocktails was insufficient to fully halt viral evolution and the emergence of viral escape with treatment has been documented [11, 33].”
Self-citationNeutralisation sensitivity of the SARS-CoV-2 omicron (B.1.1.529) variant: a cross-sectional study
Sheward, D. J., Kim, C., Ehling, R. A., Pankow, A. P., Dopico, X. C., Dyrdak, R., Martin, D. P., Reddy, S. T., Dillner, J., Hedestam, G. B. K., et al. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00129-3 · Cited by 84
The great escape? SARS-CoV-2 variants evading neutralizing responses
Prévost, J., & Finzi, A. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.02.010 · Cited by 82
Salleh, M. Z., Derrick, J. P., & Deris, Z. Z. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147425 · Cited by 88
Development and deployment of COVID-19 vaccines for those most vulnerable
Koff, W. C., Schenkelberg, T., Williams, T. M., Baric, R. S., McDermott, A. B., Cameron, C., Cameron, M. J., Frieman, M. B., Neumann, G., Kawaoka, Y., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abd1525 · Cited by 83
Phillips, A. M., Lawrence, K. R., Moulana, A., Dupic, T., Chang, J., Johnson, M. S., Cvijović, I., Mora, T., Walczak, A. M., & Desai, M. M. (2021) · eLife · doi:10.7554/elife.71393 · Cited by 96
Chen, C., Boorla, V. S., Banerjee, D., Chowdhury, R., Cavener, V. S., Nissly, R. H., Gontu, A., Boyle, N. R., Vandegrift, K. J., Nair, M. S., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2106480118 · Cited by 83
“Consequently, amino acid changes in RBD that can increase binding affinity with hACE2 and/or adversely affect antibody neutralization have been extensively mapped by high-throughput mutational studies (39, 40).”
BackgroundSARS-CoV-2 Quasispecies Provides an Advantage Mutation Pool for the Epidemic Variants
Sun, F., Wang, X., Tan, S., Dan, Y., Lu, Y., Zhang, J., Xu, J., Tan, Z., Xiang, X., Zhou, Y., et al. (2021) · Microbiology Spectrum · doi:10.1128/spectrum.00261-21 · Cited by 93
Structural basis for continued antibody evasion by the SARS-CoV-2 receptor binding domain
Smith, K. N., Clark, S. A., Shankar, S., Pan, J., Clark, L. E., Yang, P., Coscia, A., McKay, L. G. A., Varnum, H., Brusic, V., et al. (2022) · Science · doi:10.1126/science.abl6251 · Cited by 83
An engineered bispecific human monoclonal antibody against SARS-CoV-2
Li, Z., Li, S., Zhang, G., Peng, W., Chang, Z., Zhang, X., Fan, Z., Chai, Y., Wang, F., Zhao, X., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01138-w · Cited by 80
Rotondo, J. C., Martini, F., Maritati, M., Mazziotta, C., Mauro, G. D., Lanzillotti, C., Barp, N., Gallerani, A., Tognon, M. G., & Contini, C. (2021) · Viruses · doi:10.3390/v13091687 · Cited by 88
An early warning system for emerging SARS-CoV-2 variants
Subissi, L., von Gottberg, A., Thukral, L., Worp, N., Munnink, B. B. O., Rathore, S., Abu-Raddad, L. J., Aguilera, X., Alm, E., Archer, B. N., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01836-w · Cited by 84
Tao, K., Tzou, P. L., Pond, S. L. K., Ioannidis, J. P. A., & Shafer, R. W. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.00926-22 · Cited by 88
Omicron (B.1.1.529): Infectivity, vaccine breakthrough, and antibody resistancePreprint
Chen, J., Wang, R., Gilby, N. B., & Wei, G. (2021) · PubMed · doi:10.48550/arxiv.2112.01318 · Cited by 78
Highly synergistic combinations of nanobodies that target SARS-CoV-2 and are resistant to escape
Mast, F. D., Fridy, P. C., Ketaren, N. E., Wang, J., Jacobs, E. Y., Olivier, J. P., Sanyal, T., Molloy, K. R., Schmidt, F., Rutkowska, M., et al. (2021) · eLife · doi:10.7554/elife.73027 · Cited by 76
Suryadevara, N., Shrihari, S., Gilchuk, P., VanBlargan, L. A., Binshtein, E., Zost, S. J., Nargi, R. S., Sutton, R. E., Winkler, E. S., Chen, E. C., et al. (2021) · doi:10.1101/2021.01.19.427324 · Cited by 361
Gregory, D. A., Trujillo, M., Rushford, C., Flury, A. G., Kannoly, S., San, K. M., Lyfoung, D. T., Wiseman, R. W., Bromert, K. H., Zhou, M.-Y., et al. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1010636 · Cited by 80
“Changes at this position are common and are known to participate in evasion from class I neutralizing antibodies [27,28].”
InfluentialVerkhivker, G. M., Agajanian, S., Öztaş, D. Y., & Gupta, G. (2021) · Biochemistry · doi:10.1021/acs.biochem.1c00139 · Cited by 63
Revealing the Threat of Emerging SARS-CoV-2 Mutations to Antibody Therapies
Chen, J., Gao, K., Wang, R., & Wei, G. (2021) · Journal of Molecular Biology · doi:10.1016/j.jmb.2021.167155 · Cited by 76
Wang, H., Jean, S., Eltringham, R., Madison, J., Snyder, P. J., Tu, H., Jones, D. M., & Leber, A. L. (2021) · Journal of Clinical Microbiology · doi:10.1128/jcm.00926-21 · Cited by 76
Impact of COVID-19 on dental education- a scoping review
Farrokhi, F., Mohebbi, S. Z., Farrokhi, F., & Khami, M. R. (2021) · BMC Medical Education · doi:10.1186/s12909-021-03017-8 · Cited by 93
Lumley, S. F., Rodger, G., Constantinides, B., Sanderson, N., Chau, K. K., Street, T. L., O’Donnell, D., Howarth, A., Hatch, S. B., Marsden, B. D., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciab608 · Cited by 70
Zhou, H., Dcosta, B. M., Samanovic, M. I., Mulligan, M. J., Landau, N. R., & Tada, T. (2021) · mBio · doi:10.1128/mbio.01386-21 · Cited by 68
SARS-CoV-2 variants, immune escape, and countermeasures
Zhang, Y., Zhang, H. C., & Zhang, W. (2022) · Frontiers of Medicine · doi:10.1007/s11684-021-0906-x · Cited by 78
Synergistic Inhibition of SARS-CoV-2 Replication Using Disulfiram/Ebselen and Remdesivir
Chen, T., Fei, C.-Y., Chen, Y.-P., Sargsyan, K., Chang, C.-P., Yuan, H. S., & Lim, C. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00022 · Cited by 67
Yi, C., Sun, X., Lin, Y., Gu, C., Ding, L., Lü, X., Yang, Z., Zhang, Y., Ma, L., Gu, W., et al. (2021) · Genome Medicine · doi:10.1186/s13073-021-00985-w · Cited by 76
Genetic and structural basis for recognition of SARS-CoV-2 spike protein by a two-antibody cocktail
Dong, J., Zost, S. J., Greaney, A. J., Starr, T. N., Dingens, A. S., Chen, E. C., Chen, R. E., Case, J. B., Sutton, R. E., Gilchuk, P., et al. (2021) · doi:10.1101/2021.01.27.428529 · Cited by 55
Self-citationOne year into the pandemic: Short-term evolution of SARS-CoV-2 and emergence of new lineages
Gónzález‐Candelas, F., Shaw, M., Phan, T. G., Kulkarni‐Kale, U., Paraskevis, D. N., Luciani, F., Kimura, H., & Sironi, M. (2021) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2021.104869 · Cited by 69
Verkhivker, G. M., & Paola, L. D. (2021) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.1c00395 · Cited by 56
A SARS-CoV-2 variant elicits an antibody response with a shifted immunodominance hierarchy
Greaney, A. J., Starr, T. N., Eguia, R. T., Loes, A. N., Khan, K., Karim, F., Cele, S., Bowen, J. E., Logue, J. K., Corti, D., et al. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1010248 · Cited by 62
“0 (10-fold loss in RBD expression) were chosen, which filter comparable numbers of mutations as in prior Wuhan-Hu-1 experiments [28,73].”
MethodResultSelf-citationThe landscape of antibody binding affinity in SARS-CoV-2 Omicron BA.1 evolution
Moulana, A., Dupic, T., Phillips, A. M., Chang, J., Roffler, A. A., Greaney, A. J., Starr, T. N., Bloom, J. D., & Desai, M. M. (2023) · eLife · doi:10.7554/elife.83442 · Cited by 70
Self-citationTada, T., Dcosta, B. M., Zhou, H., Vaill, A., Kazmierski, W., & Landau, N. R. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.02.18.431897 · Cited by 63
Omicron BA.2 (B.1.1.529.2): high potential to becoming the next dominating variantPreprint
Chen, J., & Wei, G. (2022) · Research Square · doi:10.21203/rs.3.rs-1362445/v1 · Cited by 78
A Structural Landscape of Neutralizing Antibodies Against SARS-CoV-2 Receptor Binding Domain
Niu, L., Wittrock, K. N., Clabaugh, G. C., Srivastava, V., & Cho, M. W. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.647934 · Cited by 65
SARS-CoV-2 variants – Evolution, spike protein, and vaccines
Chen, K.-W. K., Huang, D. T., & Huang, L. (2022) · Biomedical Journal · doi:10.1016/j.bj.2022.04.006 · Cited by 73
SARS-CoV-2 Variants and Their Relevant Mutational Profiles: Update Summer 2021
Alkhatib, M., Svicher, V., Salpini, R., Ambrosio, F. A., Bellocchi, M. C., Carioti, L., Piermatteo, L., Scutari, R., Costa, G., Artese, A., et al. (2021) · Microbiology Spectrum · doi:10.1128/spectrum.01096-21 · Cited by 65
Update on SARS-CoV-2 Omicron Variant of Concern and Its Peculiar Mutational Profile
Alkhatib, M., Salpini, R., Carioti, L., Ambrosio, F. A., D’Anna, S., Duca, L., Costa, G., Bellocchi, M. C., Piermatteo, L., Artese, A., et al. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.02732-21 · Cited by 68
Ikemura, N., Taminishi, S., Inaba, T., Arimori, T., Motooka, D., Katoh, K., Kirita, Y., Higuchi, Y., Li, S., Suzuki, T., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abn7737 · Cited by 64
Onodera, T., Kita, S., Adachi, Y., Moriyama, S., Sato, A., Nomura, T., Sakakibara, S., Inoue, T., Tadokoro, T., Anraku, Y., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.08.025 · Cited by 58
A simple and fast spectroscopy-based technique for Covid-19 diagnosis
Kitane, D. L., LOUKMAN, S., Marchoudi, N., Fernández-Galiana, Á., Ansari, F. Z. E., Jouali, F., Badir, J., Gala, J., Bertsimas, D., Azami, N., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-95568-5 · Cited by 65
Focosi, D., Maggi, F., Franchini, M., McConnell, S. A., & Casadevall, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010029 · Cited by 61
Functional map of SARS-CoV-2 3CL protease reveals tolerant and immutable sites
Iketani, S., Hong, S. J., Sheng, J., Bahari, F., Culbertson, B., Atanaki, F. F., Aditham, A. K., Kratz, A., Luck, M. I., Tian, R., et al. (2022) · Cell Host & Microbe · doi:10.1016/j.chom.2022.08.003 · Cited by 62
Rochman, N. D., Faure, G., Wolf, Y. I., Freddolino, L., Zhang, F., & Koonin, E. V. (2022) · mBio · doi:10.1128/mbio.00135-22 · Cited by 61
“…mutations in 6 sites (417, 477, 484, 491, 493, and 499) that are predicted to signi fi cantly destabilize the RBD-NAb complex relative to the RBD-ACE2 complex and appear to pose a risk of vaccine escape, which is broadly consistent with the results of deep mutational scanning (8, 9, 19 – 22).”
In vitro evaluation of therapeutic antibodies against a SARS-CoV-2 Omicron B.1.1.529 isolate
Touret, F., Baronti, C., Bouzidi, H. S., & de Lamballerie, X. N. (2022) · Scientific Reports · doi:10.1038/s41598-022-08559-5 · Cited by 61
SARS-CoV-2 escape from cytotoxic T cells during long-term COVID-19
Stanevich, O. V., Alekseeva, E. I., Sergeeva, M. V., Fadeev, A. V., Komissarova, K., Ivanova, A. A., Simakova, T., Vasilyev, K., Shurygina, A.-P. S., Stukova, M., et al. (2023) · Nature Communications · doi:10.1038/s41467-022-34033-x · Cited by 65
Frank, F., Keen, M. M., Rao, A., Bassit, L., Liu, X., Bowers, H. B., Patel, A. B., Cato, M. L., Sullivan, J. A., Greenleaf, M. N., et al. (2022) · Cell · doi:10.1016/j.cell.2022.08.010 · Cited by 59
Cheng, M. H., Krieger, J. M., Kaynak, B., Arditi, M., & Bahar, I. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.01.10.426143 · Cited by 58
Taylor, A. L., & Starr, T. N. (2023) · PLoS Pathogens · doi:10.1371/journal.ppat.1011901 · Cited by 65
“These studies have revealed a general tolerance to mutations in the SARS-CoV-2 RBD, which presumably underlies the ability of this domain to continually evolve to escape antibody recognition while maintaining ACE2 binding.”
BackgroundSelf-citationUnderstanding Mutations in Human SARS-CoV-2 Spike Glycoprotein: A Systematic Review & Meta-Analysis
Kumar, R., Srivastava, Y., Muthuramalingam, P., Singh, S. K., Verma, G., Tiwari, S., Tandel, N., Beura, S. K., Panigrahi, A. R., Maji, S., et al. (2023) · Viruses · doi:10.3390/v15040856 · Cited by 63
Generation of SARS-CoV-2 escape mutations by monoclonal antibody therapy
Ragonnet‐Cronin, M., Nutalai, R., Huo, J., Dijokaite-Guraliuc, A., Das, R., Tuekprakhon, A., Supasa, P., Liu, C., Selvaraj, M., Groves, N., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37826-w · Cited by 65
A focus on the spread of the delta variant of SARS-CoV-2 in India
Novelli, G., Colona, V. L., & Pandolfi, P. P. (2021) · The Indian Journal of Medical Research · doi:10.4103/ijmr.ijmr_1353_21 · Cited by 59
A cross-cultural exploratory analysis of pandemic growth: The case of COVID-19
Dheer, R. J. S., Egri, C. P., & Treviño, L. J. (2021) · Journal of International Business Studies · doi:10.1057/s41267-021-00455-w · Cited by 63
Structural and functional insights into the spike protein mutations of emerging SARS-CoV-2 variants
Gupta, D., Sharma, P., Singh, M., Kumar, M., Ethayathulla, A. S., & Kaur, P. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-04008-0 · Cited by 60
Understanding the Secret of SARS-CoV-2 Variants of Concern/Interest and Immune Escape
Lou, F., Li, M., Pang, Z., Jiang, L., Guan, L., Tian, L., Hu, J., Fan, J., & Fan, H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.744242 · Cited by 58
COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models
Maisonnasse, P., Aldon, Y., Marc, A., Marlin, R., Dereuddre‐Bosquet, N., Kuzmina, N. A., Freyn, A. W., Snitselaar, J. L., Gonçalves, A., Caniels, T. G., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26354-0 · Cited by 61
Joshi, M. N., Kumar, M., Srivastava, V., Kumar, D., Rathore, D. S., Pandit, R. J., Graham, D. W., & Joshi, C. G. (2022) · Environmental Pollution · doi:10.1016/j.envpol.2022.119757 · Cited by 52
SARS-CoV-2 drug resistance and therapeutic approaches
Batool, S., Chokkakula, S., Jeong, J. H., Baek, Y. H., & Song, M. (2025) · Heliyon · doi:10.1016/j.heliyon.2025.e41980 · Cited by 57
Dominance of Alpha and Iota variants in SARS-CoV-2 vaccine breakthrough infections in New York City
Duerr, R., Dimartino, D., Marier, C., Zappile, P., Wang, G., Lighter, J., Elbel, B. D., Troxel, A. B., & Heguy, A. (2021) · Journal of Clinical Investigation · doi:10.1172/jci152702 · Cited by 56
Deep mutational scanning of SARS-CoV-2 Omicron BA.2.86 and epistatic emergence of the KP.3 variant
Taylor, A. L., & Starr, T. N. (2024) · Virus Evolution · doi:10.1093/ve/veae067 · Cited by 59
Self-citationRapid characterization of spike variants via mammalian cell surface display
Javanmardi, K., Chou, C., Terrace, C. I., Annapareddy, A., Kaoud, T. S., Guo, Q., Lutgens, J., Zorkic, H., Horton, A. P., Gardner, E. C., et al. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.11.024 · Cited by 56
“Next, we examined RBD mutations, 11 of which were previously reported to escape therapeutic antibodies from the REGN-COV2 cocktail (REGN10933 and REGN10987) (Figure S6) (Starr et al., 2021).”
Deep mutational scanning for therapeutic antibody engineering
Hanning, K. R., Minot, M., Warrender, A. K., Kelton, W., & Reddy, S. T. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2021.11.010 · Cited by 58
On the road to ending the COVID-19 pandemic: Are we there yet?
Case, J. B., Winkler, E. S., Errico, J. M., & Diamond, M. (2021) · Virology · doi:10.1016/j.virol.2021.02.003 · Cited by 49
Human Antibodies for Viral Infections
Crowe, J. E. (2022) · Annual Review of Immunology · doi:10.1146/annurev-immunol-042718-041309 · Cited by 57
SARS-CoV-2: phenotype, genotype, and characterization of different variants
Saberiyan, M., Karimi, E., Khademi, Z., Movahhed, P., Safi, A., & Ghahfarrokhi, A. M. (2022) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-022-00352-6 · Cited by 58
Choudhary, M. C., Chew, K. W., Deo, R., Flynn, J. P., Regan, J., Crain, C. R., Moser, C., Hughes, M. D., Ritz, J., Ribeiro, R. M., et al. (2022) · Nature Microbiology · doi:10.1038/s41564-022-01254-1 · Cited by 69
“The emergence of SARS-CoV-2 sequence changes was reported shortly after the introduction of mAbs 7,10,11 , but there has not been definitive evidence that the emergence of SARS-CoV-2 resistance mutations can lead to altered in vivo intrahost viral replication dynamics and loss of therapeutic…”
BackgroundSelf-citationMosaic sarbecovirus nanoparticles elicit cross-reactive responses in pre-vaccinated animals
Cohen, A. A., Keeffe, J. R., Schiepers, A., Dross, S., Greaney, A. J., Rorick, A. V., Gao, H., Gnanapragasam, P. N. P., Fan, C., West, A. P., et al. (2024) · Cell · doi:10.1016/j.cell.2024.07.052 · Cited by 55
Self-citationHuang, S., & Wang, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22063060 · Cited by 56
van Doremalen, N., Purushotham, J. N., Schulz, J. E., Holbrook, M. G., Bushmaker, T., Carmody, A., Port, J. R., Yinda, C. K., Okumura, A., Saturday, G. A., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.01.09.426058 · Cited by 50
Yewdell, J. W. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009509 · Cited by 48
Verkhivker, G. M., Agajanian, S., Öztaş, D. Y., & Gupta, G. (2021) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.1c00372 · Cited by 40
Tietjen, I., Cassel, J., Register, E. T., Zhou, X. Y., Messick, T. E., Keeney, F., Lu, L. D., Beattie, K. D., Rali, T., Tebas, P., et al. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00772-21 · Cited by 50
Cheng, M. H., Krieger, J. M., Banerjee, A., Xiang, Y., Kaynak, B., Shi, Y., Arditi, M., & Bahar, I. (2022) · iScience · doi:10.1016/j.isci.2022.103939 · Cited by 47
Lumley, S. F., Rodger, G., Constantinides, B., Sanderson, N., Chau, K. K., Street, T. L., O’Donnell, D., Howarth, A., Hatch, S. B., Marsden, B. D., et al. (2021) · medRxiv · doi:10.1101/2021.03.09.21253218 · Cited by 48
Harnessing Type I IFN Immunity Against SARS-CoV-2 with Early Administration of IFN-β
Vinh, D. C., Abel, L., Bastard, P., Cheng, M. P., Condino‐Neto, A., Gregersen, P. K., Haerynck, F., Cicalese, M. P., Hagin, D., Soler‐Palacín, P., et al. (2021) · Journal of Clinical Immunology · doi:10.1007/s10875-021-01068-6 · Cited by 49
Jacob, J. J., Vasudevan, K., Pragasam, A. K., Gunasekaran, K., Veeraraghavan, B., & Mutreja, A. (2021) · mBio · doi:10.1128/mbio.01188-21 · Cited by 50
Upadhyay, V., Lucas, A., Panja, S., Miyauchi, R., & Mallela, K. M. G. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.101208 · Cited by 44
“Lower ef fi cacy of some of the vaccines was reported against the emerging variants of concern (VOCs) that include alpha, beta, and gamma variants along with reports of new variants escaping the antibodies approved for emergency use (36 – 39).”
Chatterjee, D., Tauzin, A., Marchitto, L., Gong, S. Y., Boutin, M., Bourassa, C., Beaudoin-Bussières, G., Bo, Y., Ding, S., Laumaea, A., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110429 · Cited by 48
Metadata
- Authors
- Starr, T. N., Greaney, A. J., Addetia, A., Hannon, W. W., Choudhary, M. C., Dingens, A. S., Li, J. Z., & Bloom, J. D.
- Affiliations
- Fred Hutch Cancer Center (US)
- University of Washington (US)
- Brigham and Women's Hospital (US)
- Howard Hughes Medical Institute (US)
- Corresponding author
- Bloom, Jesse D.
- ORCID
- Venue
- Science
- Published
- 2021-02-19
- Volume
- 371
- Issue
- 6531
- Pages
- 850-854
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC7963219
- OpenAlex
- W3125266951
- Cited by
- 743
- References
- 40
- Citations by year
- 2026: 31 · 2025: 37 · 2024: 56 · 2023: 104 · 2022: 232 · 2021: 279
- FWCI
- 53.32
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Science (publishedVersion, cc-by)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (submittedVersion, cc-by)
- Funders
- Howard Hughes Medical Institute (Investigator)
- National Institute of Allergy and Infectious Diseases (R01AI127893, R01AI141707)
- Bill and Melinda Gates Foundation (INV-004949)
- Damon Runyon Cancer Research Foundation (DRG-2381-19)
- Massachusetts Consortium for Pathogen Readiness
- Washington Research Foundation (Innovation Fellow)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 detection and testing
- Keywords
- SARS-CoV-2, COVID-19 pandemic, antibody escape, receptor binding domain, viral mutations, monoclonal antibodies, antibody binding, viral surveillance
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.